{"id":"https://openalex.org/W2967097725","doi":null,"title":"Fully human Anti-HER3 monoclonal antibodies (mAbs) have unique in vitro and in vivo functional and antitumor activities versus other HER family inhibitors","display_name":"Fully human Anti-HER3 monoclonal antibodies (mAbs) have unique in vitro and in vivo functional and antitumor activities versus other HER family inhibitors","alternate_titles":[],"publication_year":2008,"publication_date":"2008-05-01","ids":{"openalex":"https://openalex.org/W2967097725","mag":"2967097725"},"language":"en","primary_location":{"id":"mag:2967097725","doi":null,"is_oa":false,"landing_page_url":"https://cancerres.aacrjournals.org/content/68/9_Supplement/LB-21","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Cancer Research","raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W2967097725"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112250130","display_name":"Daniel J. Freeman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel J. Freeman","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, U3 Pharma, AG, Munich, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, U3 Pharma, AG, Munich, Germany","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044732658","display_name":"Selam Ogbagabriel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Selam Ogbagabriel","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, U3 Pharma, AG, Munich, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, U3 Pharma, AG, Munich, Germany","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073283562","display_name":"Mike Rothe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mike Rothe","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, U3 Pharma, AG, Munich, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, U3 Pharma, AG, Munich, Germany","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078787495","display_name":"Robert Radinsky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Radinsky","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, U3 Pharma, AG, Munich, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, U3 Pharma, AG, Munich, Germany","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060386283","display_name":"Martin Treder","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin Treder","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, U3 Pharma, AG, Munich, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, U3 Pharma, AG, Munich, Germany","institution_ids":["https://openalex.org/I1320553840"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1320553840"],"apc_list":null,"apc_paid":null,"fwci":0.7359,"has_fulltext":false,"cited_by_count":22,"citation_normalized_percentile":{"value":0.72910796,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"68","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her3","display_name":"HER3","score":0.9700000286102295},{"id":"https://openalex.org/keywords/anti-her3-monoclonal-antibody","display_name":"anti-HER3 monoclonal antibody","score":0.9670000076293945},{"id":"https://openalex.org/keywords/pi3k-akt-signaling","display_name":"PI3K/Akt signaling","score":0.8709999918937683},{"id":"https://openalex.org/keywords/her3-phosphorylation","display_name":"HER3 phosphorylation","score":0.6570000052452087},{"id":"https://openalex.org/keywords/combination-antibody-therapy","display_name":"antibody combination therapy","score":0.5619999766349792},{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.5770000219345093},{"id":"https://openalex.org/keywords/her2-inhibitors","display_name":"HER2 inhibitors","score":0.9909999966621399},{"id":"https://openalex.org/keywords/anchorage-independent-growth","display_name":"anchorage-independent growth","score":0.6819999814033508},{"id":"https://openalex.org/keywords/lung-cancer-xenografts","display_name":"lung cancer xenografts","score":0.7820000052452087},{"id":"https://openalex.org/keywords/breast-cancer-xenografts","display_name":"breast cancer xenografts","score":0.9470000267028809},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.5519999861717224}],"concepts":[{"id":"https://openalex.org/C139770010","wikidata":"https://www.wikidata.org/wiki/Q1339807","display_name":"Internalization","level":3,"score":0.7388521432876587},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.680234432220459},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.6014344692230225},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.4973748028278351},{"id":"https://openalex.org/C75217442","wikidata":"https://www.wikidata.org/wiki/Q423650","display_name":"Protein kinase B","level":3,"score":0.4886165261268616},{"id":"https://openalex.org/C81729549","wikidata":"https://www.wikidata.org/wiki/Q4649475","display_name":"A549 cell","level":3,"score":0.47627347707748413},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4597257971763611},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4474598169326782},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.43453067541122437},{"id":"https://openalex.org/C2778560701","wikidata":"https://www.wikidata.org/wiki/Q14914188","display_name":"Neuregulin 1","level":3,"score":0.4311186671257019},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4280977249145508},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.42567822337150574},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3337220251560211},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.33137959241867065},{"id":"https://openalex.org/C11960822","wikidata":"https://www.wikidata.org/wiki/Q242736","display_name":"Phosphorylation","level":2,"score":0.3000577688217163},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.2771664261817932},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.26140904426574707},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2534409165382385},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.2503849267959595},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.15626978874206543},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2967097725","doi":null,"is_oa":false,"landing_page_url":"https://cancerres.aacrjournals.org/content/68/9_Supplement/LB-21","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Cancer Research","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2319126619","https://openalex.org/W1602828384","https://openalex.org/W4414873063","https://openalex.org/W4210322175","https://openalex.org/W2606262525","https://openalex.org/W2128477683","https://openalex.org/W2129230622","https://openalex.org/W1995097511","https://openalex.org/W2034190663","https://openalex.org/W2090355944"],"abstract_inverted_index":{"LB-21":[0],"Background:\u2028":[2],"HER3":[3,16,40,100,175,206,237,311],"is":[4,17,238],"a":[5,59,165,239],"member":[6],"of":[7,55,74,87,99,116,136,190,251,272,294,310,329,349],"the":[8,51,65,75,97,134,137,172,248,257,337,372],"Human":[9],"Epidermal":[10],"Growth":[11],"Factor":[12],"Receptor":[13],"(HER)":[14],"family.":[15],"an":[18,191],"essential":[19],"partner":[20,242],"for":[21,50,61,64,201,243],"HER":[22,66,83,88,245,282,301,322],"family":[23,67,84,89,232,246,283,323],"driven":[24],"tumorgenesis":[25],"and":[26,36,107,180,259,277,351,374],"recently":[27],"has":[28],"been":[29],"implicated":[30],"in":[31,157,215,256,290,333,336,360],"mediating":[32],"resistance":[33],"to":[34,128,199],"EGFR":[35],"HER2":[37],"inhibitors.":[38,85,284],"Though":[39],"lacks":[41],"intrinsic":[42],"kinase":[43],"activity,":[44],"it":[45,58],"contains":[46],"6":[47],"docking":[48],"sites":[49],"p85":[52],"regulatory":[53],"subunit":[54],"PI3K":[56],"making":[57],"scaffold":[60],"PI3K/AKT":[62],"signaling":[63],"via":[68],"heterodimeric":[69],"interactions.":[70],"We":[71],"report":[72],"uniqueactivities":[73],"first":[76],"fully":[77],"human":[78],"anti-HER3":[79,138,152,287,330,355],"mAbs":[80,124,139,156,197,255,268,288,331,358],"vs.":[81,253],"current":[82],"Combinations":[86],"inhibitors":[90,302,324],"were":[91,111,147,162,183,225,264],"also":[92],"explored.\u2028":[93],"Methods:\u2028":[94],"To":[95,132,170,213],"determine":[96,133,214],"inhibition":[98,293,362],"ligand-induced":[101,270],"phosphorylation,":[102],"MDA":[103,143,177,274,295,316],"MB":[104,144,178,275,296,317],"453":[105,145,179,276,297,318],"breast":[106],"A549":[108,181,222,278,338],"NSCLC":[109,223,261,339],"cells":[110,146,182,279,319],"treated":[112,148,184,226],"with":[113,149,187,230,286,354],"10":[114,150,188],"ug/ml":[115],"anti-HER3,":[117,192],"C225":[118,345],"(anti-EGFR),":[119],"c2C4":[120],"(anti-HER2)":[121],"or":[122,153,195,233,325,346],"control":[123,155,196,234,326,343],"1":[125,202],"hour":[126,203],"prior":[127,198],"heregulin-beta":[129],"(HRG)":[130],"stimulation.":[131],"activity":[135],"on":[140,174,315],"anchorage-independent":[141],"growth,":[142],"\u03bcg/ml":[151,189],"isotype":[154],"serum":[158],"containing":[159],"medium.":[160],"Colonies":[161],"quantified":[163],"using":[164],"Scanalyzer":[166],"HTS":[167],"imaging":[168],"system.":[169],"evaluate":[171],"effect":[173,305],"internalization,":[176],"at":[185,204,371],"4oC":[186],"anti-EGFR,":[193],"anti-HER2":[194],"incubation":[200],"37oC.":[205],"internalization":[207],"was":[208,364],"measured":[209],"by":[210],"confocal":[211],"microscopy.":[212],"vivo":[216],"efficacy,":[217],"mice":[218],"bearing":[219],"~200":[220],"mm3":[221],"xenografts":[224,353],"twice":[227],"per":[228],"week":[229],"anti-HER":[231],"Abs.":[235],"Since":[236],"critical":[240],"heterodimerization":[241],"other":[244,281,300,321],"members,":[247],"anti-tumor":[249],"effects":[250],"single":[252,368],"combination":[254],"Calu-3":[258,350],"H1975":[260,352],"xenograft":[262,340],"models":[263],"tested.\u2028":[265],"Results:\u2028":[266],"Anti-HER3":[267],"inhibited":[269],"pHER3":[271],"both":[273],"vs":[280,320,342],"Treatment":[285,348],"resulted":[289,332,359],">":[291],"80%":[292],"colony":[298],"formation;":[299],"had":[303],"little":[304],"(p":[306,377],"90%":[308],"reduction":[309],"cell":[312],"surface":[313],"expression":[314],"mAbs.":[327],"Administration":[328],"tumor":[334,361],"stasis":[335],"model":[341],"mAbs,":[344],"c2C4.":[347],"plus":[356],"anti-EGFR":[357],"that":[363],"greater":[365],"than":[366],"either":[367],"agent":[369],"alone":[370],"doses":[373],"schedule":[375],"used":[376]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2967097725","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2019-08-22T00:00:00"}
